Immunomodulatory Effect of Rivaroxaban Nanoparticles Alone and in Combination with Sitagliptin on Diabetic Rat Model

Immunomodulatory Effect of Rivaroxaban Nanoparticles Alone and in Combination with Sitagliptin on Diabetic Rat Model

Background: Chronic inflammation and immune dysregulation are key drivers of diabetes complications. Rivaroxaban (RX) and sitagliptin (SITA) are established therapies for thromboembolism and glycemic control, respectively. This study evaluated the novel therapeutic potential of nano-rivaroxaban (NRX...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed M. Elbadr, Heba A. Galal, Helal F. Hetta, Hassabelrasoul Elfadil, Fawaz E. Alanazi, Shereen Fawzy, Hashim M. Aljohani, Noura H. Abd Ellah, Marwa F. Ali, Ahmed K. Dyab, Esraa A. Ahmed
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Diseases
Subjects:
diabetes
nano-rivaroxaban
rivaroxaban
sitagliptin
streptozotocin
Online Access:https://www.mdpi.com/2079-9721/13/3/87
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2079-9721/13/3/87

Similar Items